Jefferies Financial Group
ESPR icon

Jefferies Financial Group’s Esperion Therapeutics ESPR Stock Holding History

Jefferies Financial Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$222K – 1530
2024
Q2 		$222K Buy
+100,000
New +$235K ﹤0.01% 1205
2023
Q4 		– Sell
-50,000
Closed -$49K – 1783
2023
Q3 		$49K Hold
50,000
– – ﹤0.01% 1511
2023
Q2 		$69.5K Hold
50,000
– – ﹤0.01% 1526
2023
Q1 		$79.5K Sell
50,000
-68,000
-58% -$351K ﹤0.01% 1462
2022
Q4 		$735K Buy
+118,000
New +$844K 0.01% 944

Other funds holding ESPR

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jefferies Financial Group's ESPR Position: Q2 2024 in Review

Jefferies Financial Group sold out of Esperion Therapeutics (ESPR) in Q2 2024, closing a stake of 63,500 shares — an estimated $149K sold.

Jefferies Financial Group first reported a position in ESPR in Q4 2022 and held it in 5 quarters. The position peaked at $5.64M in Q4 2022. 176 funds tracked by Wall St. Rank hold ESPR as of Q2 2024.

  • Jefferies Financial Group reported no remaining Esperion Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Jefferies Financial Group sold 63,500 Esperion Therapeutics shares in Q2 2024, an estimated $149K.
  • Jefferies Financial Group first reported a position in Esperion Therapeutics in Q4 2022 and held it in 5 quarters.
  • Jefferies Financial Group's Esperion Therapeutics position peaked at $5.64M in Q4 2022.
  • 176 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2024.

Based on Jefferies Financial Group's 13F filing for Q2 2024, filed 13 Aug 2024.